| N = 147 affected eyes |
---|---|
AC cell grade (number of cells per hpf) according to SUN examined after dilatation | |
 0 [< 1] | 30 (20.4%) |
 0.5+ [1–5] | 16 (10.9%) |
 1+ [6–15] | 53 (36.1%) |
 2+ [16–25] | 26 (17.7%) |
 3+ [26–50] | 9 (5.1%) |
 4+ [> 50] | 2 (1.4%) |
 Missing | 11 (7.5%) |
Visual acuity, logMAR, mean (SD) | 0.48 (0.51) |
 logMAR ≥0.1 (≤ 20/50) | 79 (66.4%) |
 logMAR ≥1 (≤ 20/200) | 5 (4.2%) |
Any structural complication | 81 (56.3%) |
 Ocular hypotony | 3 (2.1%) |
 Ocular hypertension | 6 (4.3%) |
 Posterior synechiae | 60 (43.2%) |
 Glaucoma | 6 (4.4%) |
 Cataract | 28 (19.9%) |
 Band keratopathy | 31 (21.5%) |
 Optic disc edema | 10 (10.9%) |
 Macular edema | 14 (21.5%) |
 Epiretinal membrane formation | 7 (11.3%) |
 Vitreous haze, mean (SD) | 1.37 (0.92) |
 Other complications | 12 (12.8%) |
Concomitant ocular uveitis treatment | |
 Previous subtenon / intraocular steroid injections | 2 (1.4%) |
 Topical corticosteroid medication | 76 (51.7%) |
 Glaucoma medication | 10 (6.8%) |